Latest Breaking News On - Bio investors - Page 1 : comparemela.com

Passage Bio To Present At Guggenheim Healthcare Talks 6Th Annual Biotechnology Conference

Passage Bio To Present At Guggenheim Healthcare Talks 6Th Annual Biotechnology Conference
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesMike beyerWilliam chouMadeline nafusPassage bio incSam brown incGuggenheim healthcare talksAnnual biotechnology conferencePassage bioBio investorsBio media

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that

United statesMike beyerWilliam chouMadeline nafusPassage bio incSam brown incHealthcare communicationsGuggenheim healthcare talksAnnual biotechnology conferencePassage bioBio investorsBio media

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced.

United statesUniversity of pennsylvaniaStuart hendersonMike beyerHealthcare communicationsSam brown incUniversity of pennsylvania gene therapy programPassage bio incNasdaq listing rulePassage bioInducement optionsGene therapy programBio investorsBio media

Passage Bio to Present at Guggenheim s 5th Annual Inflammation, Neurology & Immunology Conference - Passage Bio (NASDAQ:PASG)

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,

United statesUniversity of pennsylvaniaMike beyerWilliam chouStuart hendersonUniversity of pennsylvania gene therapy programSam brown incHealthcare communicationsPassage bio incAnnual inflammationImmunology conferencePassage bioGene therapy programBio investorsBio media

Passage Bio to Present at Guggenheim s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

University of pennsylvaniaUnited statesStuart hendersonMike beyerWilliam chouPassage bio incSam brown incHealthcare communicationsUniversity of pennsylvania gene therapy programAnnual inflammationImmunology conferencePassage bioGene therapy programBio investorsBio mediaChief executive officer